Effects of acetazolamide on linear growth in children with pseudotumor cerebri syndrome.

acetazolamide growth idiopathic intracranial hypertension (IIH) pseudotumor cerebri (PTC) weight

Journal

Frontiers in ophthalmology
ISSN: 2674-0826
Titre abrégé: Front Ophthalmol (Lausanne)
Pays: Switzerland
ID NLM: 9918419176106676

Informations de publication

Date de publication:
2022
Historique:
received: 12 09 2022
accepted: 28 12 2022
medline: 6 2 2023
pubmed: 6 2 2023
entrez: 10 7 2024
Statut: epublish

Résumé

While oral acetazolamide is a cornerstone of management of adult and pediatric PTCS, previous studies have suggested that acetazolamide used in children with other conditions may influence growth. Retrospective chart review involving a single tertiary medical center. Thirty-four children with definite or probable PTCS were identified. Analysis was restricted to individuals from whom anthropometric data were available Half of individuals (n=11/22) showed a decline in BMI Z-scores. Sixty-three percent (n=14/22) showed a decrease in height Z-scores during treatment with acetazolamide; in 6 of these 14 children who had complete data, 3 showed at least a partial recovery of height Z-scores after discontinuation of acetazolamide. Acetazolamide may be associated with growth suppression in some children treated for pediatric PTCS. In some cases, the growth suppression appears to reverse once the acetazolamide is stopped.

Sections du résumé

Background/introduction UNASSIGNED
While oral acetazolamide is a cornerstone of management of adult and pediatric PTCS, previous studies have suggested that acetazolamide used in children with other conditions may influence growth.
Aims and methods UNASSIGNED
Retrospective chart review involving a single tertiary medical center. Thirty-four children with definite or probable PTCS were identified. Analysis was restricted to individuals from whom anthropometric data were available
Results UNASSIGNED
Half of individuals (n=11/22) showed a decline in BMI Z-scores. Sixty-three percent (n=14/22) showed a decrease in height Z-scores during treatment with acetazolamide; in 6 of these 14 children who had complete data, 3 showed at least a partial recovery of height Z-scores after discontinuation of acetazolamide.
Conclusion UNASSIGNED
Acetazolamide may be associated with growth suppression in some children treated for pediatric PTCS. In some cases, the growth suppression appears to reverse once the acetazolamide is stopped.

Identifiants

pubmed: 38983548
doi: 10.3389/fopht.2022.1042529
pmc: PMC11182249
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1042529

Informations de copyright

Copyright © 2023 Sheldon, Reggie, Paley, McCormack and Liu.

Déclaration de conflit d'intérêts

SR was employed by the company Ophthalmic Plastic & Cosmetic Surgery. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Claire A Sheldon (CA)

Department of Ophthalmology, University of British Columbia, Vancouver, BC, Canada.

Sara N Reggie (SN)

Ophthalmic Plastic & Cosmetic Surgery, Inc., St. Louis, MO, United States.

Grace L Paley (GL)

Department of Ophthalmology, Washington University, St. Louis, MO, United States.

Shana E McCormack (SE)

Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States.

Grant T Liu (GT)

Neuro-ophthalmology Service, Division of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.

Classifications MeSH